Stock A068270 CELLTRION, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Celltrion, Inc.

Equities

A068270

KR7068270008

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-07-02 pm EDT 		5-day change 1st Jan Change
181,800 KRW -1.46% Intraday chart for Celltrion, Inc. +2.83% -9.78%
Jul. 01 S.Korean shares rise on robust data; battery, biopharma stocks jump RE
Jun. 17 Celltrion Reveals Positive Phase III Results of Rheumatoid Arthritis Drug MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
S.Korean shares rise on robust data; battery, biopharma stocks jump
RE
Preliminary Injunction Issued Against Samsung Bioepis In Aflibercept BPCIA Litigation
AQ
Celltrion Reveals Positive Phase III Results of Rheumatoid Arthritis Drug
MT
Celltrion, Inc. announces an Equity Buyback for 410,734 shares.
CI
Celltrion Showcases Promising Results in Phase III study for CT-P47, A Biosimilar Candidate of Roactemra® (Tocilizumab) in Patients with Rheumatoid Arthritis (RA) at EULAR 2024
CI
Celltrion, Inc. authorizes a Buyback Plan.
CI
Amgen Files BPCIA Complaint Against Celltrion Regarding Denosumab
AQ
European Biosimilar Regulatory Update
AQ
Celltrion's Avastin Biosimilar Gains 12% Market Share in Japan
MT
AbbVie's tight grip on Humira market raises concerns about biosimilars
RE
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on April 17, 2024.
CI
Celltrion, Inc.'s Equity Buyback announced on April 17, 2024, has closed with 436,047 shares, representing 0.21% for KRW 80,550.32 million.
CI
Celltrion Receives European Commission Approval of Omlyclo® (CT-P39), the First and Only Omalizumab Biosimilar Approved in Europe
CI
Celltrion - Reality TV Star, Mollie Pearce, Backs Campaign to Tackle Inequalities in Condition That Impacts Millions of People Globally
AQ
Celltrion USA announces two-year data for ZYMFENTRA(infliximab-dyyb) to be presented at Digestive Disease Week (DDW) 2024 Conference
AQ
Celltrion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Court Cancels Injunction Hearings In Aflibercept BPCIA Litigation; Regeneron May Seek Temporary Restraining Orders
AQ
Celltrion's Q1 Attributable Profit Slumps 86%
MT
Market Share of Celltrion’s Remsima Rises to 74% in Europe
MT
MDL Panel Grants Transfer Of Aflibercept BPCIA Case
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A068270 Stock
  4. News Celltrion, Inc.